Biemond syndrome type 2

Biemond syndrome type 2 is an extremely rare genetic disorder first described by the Dutch neurologist A. Biemond in 1934. It is characterized by a combination of distinctive clinical features including iris coloboma (a gap or defect in the iris of the eye), obesity, hypogonadism (underdevelopment or reduced function of the gonital organs), postaxial polydactyly (extra fingers or toes on the outer side of the hands or feet), and intellectual disability. Some overlap in clinical features has been noted with Bardet-Biedl syndrome, though Biemond syndrome type 2 is considered a distinct entity, particularly due to the presence of iris coloboma rather than retinal dystrophy as the primary ocular finding. The syndrome affects multiple body systems including the eyes, the endocrine system (through hypogonadism and obesity), the skeletal system (polydactyly), and the central nervous system (cognitive impairment). The condition is thought to follow an autosomal recessive inheritance pattern, though the genetic basis has not been fully elucidated and the responsible gene(s) have not been definitively identified. Onset of recognizable features is typically at birth or during early childhood, with polydactyly and iris coloboma being apparent at birth and obesity and hypogonadism becoming more evident over time. There is currently no specific or curative treatment for Biemond syndrome type 2. Management is symptomatic and supportive, addressing individual clinical features. This may include surgical correction of polydactyly, hormonal therapy for hypogonadism, dietary and lifestyle interventions for obesity, educational support for intellectual disability, and ophthalmological monitoring for visual issues related to iris coloboma. Given the extreme rarity of this condition, only a very small number of cases have been reported in the medical literature, and comprehensive natural history data remain limited.

Common questions about Biemond syndrome type 2